Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current treatment strategies of oesophageal carcinoma

Current treatment strategies of oesophageal carcinoma Recent progress in the prognosis of patients with oesophageal cancer appears rather to reflect better patient selection and improved perioperative management than efficacy of the therapy. There are still a lot of controversies regarding treatment strategies due to lack of studies with adequate patient numbers and the inclusion of heterogeneous study populations. Surgery alone showed high rates of locoregional and distant failure for patients with locally advanced stages and consequently a 3 y-survival rate of only 15–20%. Postoperative radiotherapy and chemotherapy were usually not feasible due to the morbidity of the oesophagectomy. Preoperative chemotherapy showed a significant but only modest improvement in overall survival over surgery alone. Most studies investigating neoadjuvant chemoradiation were under-powered and showed no significant difference; however, in several meta-analyses a significant reduction of tumour related death rate could be shown at the expense of an increased postoperative mortality. Two European trials randomized mainly squamous cell cancer patients to chemoradiation with or without surgery. The designs of these two trials were slightly different. Both showed an increased mortality rate linked with surgery, a better locoregional control with surgery and no significant difference of overall survival according to their prospective hypothesis. The results of these trials have been controversially discussed. No general guideline of a treatment strategy is possible, because too many variables have to be considered such as histology, tumour localization, response to neoadjuvant therapy, co-morbidity, performance status and age of the patient. Personal conclusions and recommendations of the authors were discussed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Current treatment strategies of oesophageal carcinoma

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/current-treatment-strategies-of-oesophageal-carcinoma-cqsQnZ0GZ9
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0256-5
Publisher site
See Article on Publisher Site

Abstract

Recent progress in the prognosis of patients with oesophageal cancer appears rather to reflect better patient selection and improved perioperative management than efficacy of the therapy. There are still a lot of controversies regarding treatment strategies due to lack of studies with adequate patient numbers and the inclusion of heterogeneous study populations. Surgery alone showed high rates of locoregional and distant failure for patients with locally advanced stages and consequently a 3 y-survival rate of only 15–20%. Postoperative radiotherapy and chemotherapy were usually not feasible due to the morbidity of the oesophagectomy. Preoperative chemotherapy showed a significant but only modest improvement in overall survival over surgery alone. Most studies investigating neoadjuvant chemoradiation were under-powered and showed no significant difference; however, in several meta-analyses a significant reduction of tumour related death rate could be shown at the expense of an increased postoperative mortality. Two European trials randomized mainly squamous cell cancer patients to chemoradiation with or without surgery. The designs of these two trials were slightly different. Both showed an increased mortality rate linked with surgery, a better locoregional control with surgery and no significant difference of overall survival according to their prospective hypothesis. The results of these trials have been controversially discussed. No general guideline of a treatment strategy is possible, because too many variables have to be considered such as histology, tumour localization, response to neoadjuvant therapy, co-morbidity, performance status and age of the patient. Personal conclusions and recommendations of the authors were discussed.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 30, 2011

References

  • Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer
    Lightdale, CJ; Kulkarni, KG
  • High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas
    Bollschweiler, E; Baldus, SE; Schröder, W
  • Early squamous cell carcinoma of the oesophagus: the Japanese viewpoint
    Takubo, K; Aida, J; Sawabe, M; Kurosumi, M; Arima, M; Fujishiro, M; Arai, T
  • Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901
    Mariette, AC; Seitz, JF; Maillard, E; Mornex, F; Thomas, PA; Raoul, J; Boige, V; Pezet, D; Genet, C; Bedenne, L
  • The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection
    Peyre, C; Hagen, J; DeMeester, S
  • Surgical therapy of oesophageal carcinoma
    Muller, JM; Erasmi, H; Stelzner, M; Zieren, U; Pichlmaier, H
  • A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907)
    Igaki, H; Kato, H; Ando, N
  • Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer
    Kelsen, DP; Ginsberg, R; Pajak, TF; Sheahan, DG; Gunderson, L; Mortimer, J; Estes, N; Haller, DG; Ajani, J; Kocha, W; Minsky, BD; Roth, JA
  • Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma
    Thirion, PG; Michiels, S; Le Maître, A; Tierney, J
  • Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study
    Gaast, AV; van Hagen, P; Hulshof, M; Richel, D; van Berge Henegouwen, MI; Nieuwenhuijzen, GA; Plukker, JT; Bonenkamp, JJ; Steyerberg, EW; Tilanus, HW
  • Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
    Herskovic, A; Martz, K; al-Sarraf, M; Leichman, L; Brindle, J; Vaitkevicius, V; Cooper, J; Byhardt, R; Davis, L; Emami, B
  • Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102
    Bedenne, L; Michel, P; Bouche, O
  • Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
    Stahl, M; Stuschke, M; Lehmann, N
  • Is there really enough evidence to abandon surgery after radio-chemotherapy in esophageal cancer?
    Ruhstaller, T; Mueller, A; Koeberle, D; Thuerlimann, B
  • Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma ?
    Ruhstaller, T; Thuerlimann, B; von Moos, R; Koeberle, D
  • Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced oesophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
    Ribi, K; Koeberle, D; Schuller, JC; Honegger, H; Roth, A; Hess, V; Moosmann, P; von Moos, R; Borner, M; Lombriser, N; Pestalozzi, B; Ruhstaller, T
  • Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus
    Hulscher, JB; van Sandick, JW; de Boer, AG; Wijnhoven, BP; Tijssen, JG; Fockens, P; Stalmeier, PF; ten Kate, FJ; van Dekken, H; Obertop, H; Tilanus, HW; van Lanschot, JJ
  • Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up
    Stahl, M; Budach, W; Meyer, HJ; Cervantes, A